Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VOR vs PGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

PGEN Overall Winner 6-Pillar Tally: VOR 1 – 5 PGEN Matrix Metrics: VOR 3 – 7 PGEN

As of Nov 16, 2026, Precigen, Inc. (PGEN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin), whereas PGEN carries 60.2/100 (BUY) at $4.33 (7.3x Forward P/E, 21.4% operating margin).

  • Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile PGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VOR vs PGEN
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87
PGEN NASDAQ Head-to-Head Winner
Precigen, Inc. Common Stock
Pharmaceutical Preparations
$4.33
-4.63% 1D
Market Cap $1.7B
TTM Revenue $254M
Forward P/E 7.3x
Beta / 30D Vol 1.74β · 122% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 63.0 Fund 65.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 33
RSI-14: 32.6 · SMA20: $5.48 · SMA50: $6.69

6-Pillar Scorecard Institutional Category Breakdown (VOR 1 – 5 PGEN)

Columns: Metric · VOR · PGEN
1. Valuation Multiples PGEN
Forward P/E N/M 7.3x
Trailing P/E 0.1x 42.4x
PEG Ratio N/M N/M
EV / Revenue N/M 7.1x
2. Growth & Scale PGEN
Revenue Growth (YoY) +0.0% +2437.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $254M
Market Cap $1.2B $1.7B
3. Profitability & Quality PGEN
Gross Margin N/A 74.5%
Operating Margin 0.0% 21.4%
Net Profit Margin 0.0% 15.6%
Return on Equity (ROE) -125.4% 38.8%
4. Balance Sheet & Cash Flow PGEN
Cash Generation (TTM) -$1.63B -$120M
Cash Flow Margin N/A -47.4%
Net Cash / Leverage $1.04B Net Cash $135M Net Debt (1.18x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 127.0% (6th %ile) 84.8% (11th %ile)
Put/Call OI Skew 2.03x (Put-Skewed) 0.06x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat PGEN
OpEx & R&D Intensity N/A 53.1% of Rev ($135M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VOR (3) vs PGEN (7)
Institutional Metric VOR PGEN Criterion Row Edge
Market Capitalization
Scale
$1.2B $1.7B Larger Scale PGEN
Trailing P/E Ratio
Valuation
0.1x 42.4x Lower Multiple VOR
Forward P/E Ratio
Valuation
N/M 7.3x Lower Multiple PGEN
Revenue Growth (YoY)
Growth
+0.0% +2437.6% Higher Growth PGEN
Operating Margin (TTM)
Profitability
0.0% 21.4% Higher Margin PGEN
Net Profit Margin
Profitability
0.0% 15.6% Higher Margin PGEN
Return on Equity (ROE)
Capital Efficiency
-125.4% 38.8% Higher ROE PGEN
52-Week Range Position
Momentum
65% ($6–$26) 22% ($3–$9) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.91β · 61% Vol 1.74β · 122% Vol Lower Realized Risk VOR
Unified Institutional Score
Composite Signal
57.8 / 100 (HOLD) 60.2 / 100 (BUY) Higher Composite PGEN
Trailing 12M Revenue (USD)
Operating Scale
N/A $254M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 74.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.63B ($1.04B Net Cash) -$120M ($135M Net Debt (1.18x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +39.0 pp
VOR: +6.82% · PGEN: -32.18%
3M Horizon VOR +18.58 pp
VOR: -17.27% · PGEN: -35.85%
6M Horizon VOR +29.92 pp
VOR: +36.31% · PGEN: +6.39%
1Y Horizon VOR +85.36 pp
VOR: +97.54% · PGEN: +12.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs PGEN. Trailing 12-month operating profitability (VOR 0.0% vs PGEN 21.4%) and valuation multiples (VOR N/M vs PGEN 7.3x Forward P/E) are benchmarked directly in Pillar 4 below.

VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M
PGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$254M
Gross Margin74.5%
Op. Margin21.4%
ROE / Fwd P/E38.8% · 7.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PGEN BREAKDOWN
61d in phase · OBV DISTRIBUTION
Current IV 84.8%
IV Percentile 11th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 21.4% operating margin.
OpEx & R&D Reinvestment 53.1% of Rev ($135M)
90D Engineering Disclosures 0 Published

Investor FAQ VOR vs PGEN Key Questions & Quantitative Answers

As of Nov 16, 2026, Precigen, Inc. (PGEN) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin), whereas PGEN carries 60.2/100 (BUY) at $4.33 (7.3x Forward P/E, 21.4% operating margin). Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile PGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PGEN leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PGEN at +2437.6% YoY revenue growth and +0.0% YoY earnings growth on $254M TTM revenue (74.5% gross margin, 21.4% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $254M for PGEN. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus 53.1% of Rev ($135M) (0 disclosures) for PGEN.

PGEN screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PGEN trades at 7.3x Forward P/E, 42.4x Trailing P/E, N/M PEG, and 7.1x EV/Revenue (-47.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus PGEN (38.8% ROE) capital efficiency.

In options market volatility and institutional positioning, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk). By comparison, PGEN carries 84.8% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 122% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.